HRTX - Why Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday? | Benzinga
Tuesday, Heron Therapeutics Inc (NASDAQ:HRTX) reported a fourth-quarter 2023 EPS of $(0.07), beating the consensus of $(0.16).
Sales increased 14% Y/Y to $34.23 million, beating the consensus of $30.98 million due to stronger upticks in Zynrelef, Cinvanti, and Sustol.
“In the fourth quarter of 2023, Heron saw continued positive momentum and an increased sales trajectory in both our acute care and oncology care franchises, illustrating how the strategic decisions made over the past year have positioned the Company for long-term success and profitability,” said Craig Collard, Chief Executive Officer of ...